BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35597058)

  • 21. [Thoracic
    Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathological features and prognosis of SMARCA4-deficient non-small cell lung carcinoma: an analysis of 127 cases].
    Li SL; Wu CY; Zhang LP; Huang Y; Wu W; Zhang W; Hou LK
    Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):665-670. PubMed ID: 37408395
    [No Abstract]   [Full Text] [Related]  

  • 23. Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab.
    Lin YT; Li CF; Wu HC; Jan YH; Kuo YH
    Front Immunol; 2023; 14():1131448. PubMed ID: 37051241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic Characteristics of BRG1-Deficient NSCLC.
    Dagogo-Jack I; Schrock AB; Kem M; Jessop N; Lee J; Ali SM; Ross JS; Lennerz JK; Shaw AT; Mino-Kenudson M
    J Thorac Oncol; 2020 May; 15(5):766-776. PubMed ID: 31988001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
    Rekhtman N; Montecalvo J; Chang JC; Alex D; Ptashkin RN; Ai N; Sauter JL; Kezlarian B; Jungbluth A; Desmeules P; Beras A; Bishop JA; Plodkowski AJ; Gounder MM; Schoenfeld AJ; Namakydoust A; Li BT; Rudin CM; Riely GJ; Jones DR; Ladanyi M; Travis WD
    J Thorac Oncol; 2020 Feb; 15(2):231-247. PubMed ID: 31751681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
    Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
    Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
    Nambirajan A; Jain D
    Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Genomic Landscape of
    Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
    Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
    Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
    Cheung AH; Wong KY; Chau SL; Xie F; Mui Z; Li GY; Li MSC; Tong J; Ng CS; Mok TS; Kang W; To KF
    Pathology; 2024 Jun; 56(4):504-515. PubMed ID: 38413251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.
    Gupta M; Concepcion CP; Fahey CG; Keshishian H; Bhutkar A; Brainson CF; Sanchez-Rivera FJ; Pessina P; Kim JY; Simoneau A; Paschini M; Beytagh MC; Stanclift CR; Schenone M; Mani DR; Li C; Oh A; Li F; Hu H; Karatza A; Bronson RT; Shaw AT; Hata AN; Wong KK; Zou L; Carr SA; Jacks T; Kim CF
    Cancer Res; 2020 Sep; 80(18):3841-3854. PubMed ID: 32690724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology.
    Kezlarian B; Montecalvo J; Bodd FM; Chang JC; Riedel E; White C; Rekhtman N; Sauter JL
    Cancer Cytopathol; 2023 Aug; 131(8):526-534. PubMed ID: 37278102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.
    Medina PP; Romero OA; Kohno T; Montuenga LM; Pio R; Yokota J; Sanchez-Cespedes M
    Hum Mutat; 2008 May; 29(5):617-22. PubMed ID: 18386774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization.
    Orvis T; Hepperla A; Walter V; Song S; Simon J; Parker J; Wilkerson MD; Desai N; Major MB; Hayes DN; Davis IJ; Weissman B
    Cancer Res; 2014 Nov; 74(22):6486-6498. PubMed ID: 25115300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Alterations in Undifferentiated Malignant Tumors with Rhabdoid Phenotype and Loss of BRG1 Immunoexpression Identified by Fine Needle Aspirates.
    Mei L; Alikhan M; Mujacic I; Parilla M; Antic T
    Acta Cytol; 2019; 63(5):438-444. PubMed ID: 31230044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene silencing associated with SWI/SNF complex loss during NSCLC development.
    Song S; Walter V; Karaca M; Li Y; Bartlett CS; Smiraglia DJ; Serber D; Sproul CD; Plass C; Zhang J; Hayes DN; Zheng Y; Weissman BE
    Mol Cancer Res; 2014 Apr; 12(4):560-70. PubMed ID: 24445599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
    Chatzopoulos K; Boland JM
    Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.